3 ASX Stocks Trading at 52-Week Lows to Watch Now

The following three ASX stocks at 52-week lows are solid buying opportunities at current valuations backed by impressive growth trajectories.

Best asx shares to buy

Eagers Automotive Limited (ASX: APE) is engaged in the management of automotive dealerships, its major activities include the sale of used vehicles, distribution and sale of parts along with repair and servicing of vehicles.

APE has reported FY26, revenue of $665 million that is up by 11% year-on-year while the EBITDA has increased 17% to $21.9 million. The company’s year-end cash position stood at $123 million following a $30 million share buyback reflecting its position

The company is focused on strengthening its market position through its dealership network and improving operational efficiency. Its future growth will depend on vehicle demand with margin performance and its ability to achieve the FY27 earnings target. The established dealership network and diversified brand portfolio provide a platform to capture demand across various vehicle segments.

APE would benefit from the demand across the Australian automotive market with continued improvement in operating performance. Investors should monitor consumer spending conditions and competition as these factors may influence vehicle sales and profitability.

Imricor Medical Systems Inc (ASX: IMR) is a medical device company which engages in the design, manufacturing and distribution of magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures.

The company has achieved four FDA clearances in 1H26, and U.S. commercial launch initiated with Rady Children's Hospital as the first customer for NorthStar establishing a radiation-free cardiac catheterisation program.

Quarter 2 CY2026 revenue was US$60.5k down by 6% year-over-year due to clinical trial device usage which is not recognized as revenue.

The net loss for the quarter was US$7.4m a 5% improvement year-over-year reflecting lower non-cash charges but higher clinical and commercial costs.

IMR’s Focus for H2 CY2026 is on converting the U.S. hospital pipeline into NorthStar sales and scaling commercial operations.

The anticipated FDA clearances for additional capital equipment’s is expected to broaden U.S. product offerings, it’s important for company as US market offers significant scale with over 2,250 hospitals targeted for MR-guided cardiac procedures.

Australian Rare Earths Limited (ASX: AR3) Is a mineral exploration company which focuses on minerals exploration for clean energy metals including rare earths and uranium in Australia.

The company has made strong progress during the September 2026 quarter, with its Koppamurra pilot plant at ANSTO moving into continuous processing. The first processing cycle generated around 5,000 litres of pregnant leach solution, which was then processed to produce Mixed Rare Earth Hydroxide marking an important step towards developing its final rare earth product.

The company is targeting the completion of the pilot program to support its Definitive Feasibility Study planned to commence in early 2027.

At its overland project AR3 is also exploring a niobium and rare earth carbonatite system and the follow-up drilling identified an interpreted 130-metre carbonatite intersection at around 5 km south of the original discovery which is extending the potential scale of the mineral system.

The company has reported the cash reserves of $4.81 million at 30 September 2026 and received a further $1.02 million R&D tax incentive refund after the quarter.

(Source: Company Announcements)